20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Trevi Therapeutics Inc (TRVI) operates in the BIOTECHNOLOGY industry and is headquartered in New Haven, United States with about 34 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, TRVI reported $0M in revenue and ($43M) in net income.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($60M) | ($49M) | ($52M) | ($34M) | ($30M) | ($32M) | ($32M) | ($27M) | ($18M) | ($8M) | ($9M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($51M) | ($43M) | ($48M) | ($29M) | ($29M) | ($34M) | ($33M) | ($26M) | ($21M) | ($13M) | ($11M) |
| Net Margin % | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($51M) | ($43M) | ($48M) | ($29M) | ($30M) | ($33M) | ($32M) | ($27M) | ($18M) | ($8M) | ($9M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | -26.0% | — |
| Operating Income (EBIT) | ($21M) | ($15M) | ($10M) | ($14M) | ($14M) | ($11M) | ($12M) | ($14M) |
| Operating Margin % | — | — | — | — | — | — | -8385.6% | — |
| Net Income | ($18M) | ($13M) | ($8M) | ($12M) | ($12M) | ($10M) | ($11M) | ($13M) |
| Net Margin % | — | — | — | — | — | — | -7818.5% | — |
| EBITDA | ($18M) | ($13M) | ($8M) | ($12M) | ($12M) | ($10M) | ($11M) | ($13M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($53M) | ($42M) | ($38M) | ($32M) | ($28M) | ($29M) | ($29M) | ($23M) | ($18M) | ($8M) | ($11M) |
| Capital Expenditures (CapEx) | $14M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($66M) | ($42M) | ($38M) | ($32M) | ($28M) | ($29M) | ($29M) | ($23M) | ($18M) | ($8M) | ($11M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | — | $2M | $0M | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($17M) | ($17M) | ($8M) | ($11M) | ($10M) | ($13M) | ($10M) | ($10M) |
| Capital Expenditures (CapEx) | $0M | $0M | $13M | $0M | $0M | $13M | $0M | $0M |
| Free Cash Flow (FCF) | ($18M) | ($17M) | ($21M) | ($11M) | ($10M) | ($27M) | ($10M) | ($10M) |
| FCF Margin % | — | — | — | — | — | — | -6545.9% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TRVI viewer.
About TickerBase · Data methodology & sources · Privacy · Terms